Redeye considers the deal with CASI as a validation of the BI-1206 project from a commercial partner and a possible expansion of the sales potential to include the Greater China market. Also, BioInvent receives an initial payment of USD 5m plus SEK 61m through a directed issue. We expect to raise the pipeline value of BioInvent in our model by some 10 percent.